PegBio Co., Ltd. (PegBio) announced that Visepegenatide injection, marketed as Paidakang®, has been formally added to China’s National Reimbursement Drug List (NRDL) for 2026, positioning the once-weekly glucagon-like peptide-1 receptor agonist for broad insurance coverage across the country’s healthcare system. The decision by the National Healthcare Security Administration represents the company’s first successful transition from R&D to large-scale commercialization.
Paidakang®, a National Class 1 innovative drug approved in November 2025 for adult type 2 diabetes mellitus (T2DM), offers direct treatment initiation without dose titration. Pivotal trial data cited in the announcement confirm sustained and stable glycaemic control, differentiating the therapy within China’s expanding GLP-1RA segment.
China’s sizeable T2DM population underscores the commercial relevance of NRDL access. Reimbursement is expected to materially improve patient affordability, accelerate hospital listing, and enlarge nationwide market penetration for Paidakang®. PegBio has already established a commercialization collaboration framework and plans to intensify efforts with partners to widen hospital access, expand distribution channels, and promote clinical adoption as NRDL policies roll out.
The Board views NRDL inclusion as a critical inflection point that strengthens the product’s competitive position and provides fresh momentum for future revenue growth. Management, however, warns that actual sales performance will depend on market environment, market-access execution, and the pace of promotional activities.
PegBio intends to continue advancing its metabolic-disease portfolio while focusing on clinically differentiated solutions to create sustained value for shareholders.
Comments